Free Trial
NYSE:NVS

Novartis (NVS) Stock Price, News & Analysis

$104.93
0.00 (0.00%)
(As of 06/18/2024 ET)
Today's Range
$104.86
$105.56
50-Day Range
$92.57
$106.13
52-Week Range
$92.19
$108.78
Volume
1.05 million shs
Average Volume
1.25 million shs
Market Capitalization
$214.48 billion
P/E Ratio
14.16
Dividend Yield
2.32%
Price Target
$116.67

Novartis MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
11.2% Upside
$116.67 Price Target
Short Interest
Healthy
0.20% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
1.47mentions of Novartis in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
12.52%
From $7.27 to $8.18 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.08 out of 5 stars

Medical Sector

383rd out of 913 stocks

Pharmaceutical Preparations Industry

176th out of 430 stocks

NVS stock logo

About Novartis Stock (NYSE:NVS)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

NVS Stock Price History

NVS Stock News Headlines

[Urgent] Protect your money before November
Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.
[Urgent] Protect your money before November
Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/23/2024
Today
6/18/2024
Next Earnings (Estimated)
7/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
76,057
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$116.67
High Stock Price Target
$120.00
Low Stock Price Target
$114.00
Potential Upside/Downside
+11.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$14.85 billion
Pretax Margin
20.00%

Debt

Sales & Book Value

Annual Sales
$45.44 billion
Cash Flow
$11.03 per share
Book Value
$22.87 per share

Miscellaneous

Outstanding Shares
2,044,000,000
Free Float
2,043,796,000
Market Cap
$214.50 billion
Optionable
Optionable
Beta
0.58

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Vasant Narasimhan M.D. (Age 48)
    Chief Executive Officer
    Comp: $8.01M
  • Mr. Harry Kirsch (Age 59)
    Chief Financial Officer
    Comp: $3.99M
  • Mr. Victor Bulto (Age 46)
    President of US
    Comp: $3.28M
  • Dr. Patrick Horber M.D. (Age 54)
    President of International
    Comp: $7.31M
  • Dr. Steffen Lang Ph.D. (Age 57)
    President of Operations
    Comp: $2.34M
  • Paul Penepent
    Head of Group Financial Reporting and Accounting
  • Ms. Sloan Simpson
    Global Head of Investor Relations
  • Dr. Klaus Moosmayer Ph.D. (Age 56)
    Chief Ethics, Risk & Compliance Officer
    Comp: $1.55M
  • Ms. Karen L. Hale (Age 56)
    Chief Legal Officer
    Comp: $2.34M
  • Dr. Robert Kowalski Pharm.D. (Age 56)
    Chief People & Organization Officer
    Comp: $2.1M

Should I Buy Novartis Stock? NVS Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Novartis AG:

  • Novartis AG has shown strong revenue growth in recent quarters, indicating a positive financial performance.
  • The company's innovative pipeline of pharmaceutical products, including the latest treatments, positions it well for future growth and market competitiveness.
  • Novartis AG's current stock price is undervalued compared to its peers in the pharmaceutical industry, presenting a potential buying opportunity for investors.
  • Recent strategic acquisitions and partnerships have expanded Novartis AG's global reach and diversified its product portfolio, reducing dependency on any single market or product.
  • The company's commitment to research and development ensures a steady stream of new products and treatments, enhancing long-term sustainability and profitability.

Cons

Investors should be bearish about investing in Novartis AG for these reasons:

  • Regulatory challenges and uncertainties in the pharmaceutical industry can impact Novartis AG's product approvals and market access, leading to potential setbacks.
  • Intense competition from other pharmaceutical companies may pressure Novartis AG's market share and pricing power, affecting its revenue and profitability.
  • Fluctuations in currency exchange rates can expose Novartis AG to foreign exchange risks, impacting its financial performance and earnings in different markets.
  • Global economic conditions and healthcare policies can influence demand for Novartis AG's products, potentially affecting sales and revenue growth.
  • Unexpected adverse events related to Novartis AG's products or legal disputes could lead to reputational damage and financial liabilities, impacting investor confidence.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 8, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

NVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price target for 2024?

4 brokers have issued 12 month price targets for Novartis' shares. Their NVS share price targets range from $114.00 to $120.00. On average, they expect the company's stock price to reach $116.67 in the next year. This suggests a possible upside of 11.2% from the stock's current price.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How have NVS shares performed in 2024?

Novartis' stock was trading at $100.97 on January 1st, 2024. Since then, NVS stock has increased by 3.9% and is now trading at $104.93.
View the best growth stocks for 2024 here
.

Are investors shorting Novartis?

Novartis saw a decrease in short interest in May. As of May 31st, there was short interest totaling 3,920,000 shares, a decrease of 23.6% from the May 15th total of 5,130,000 shares. Based on an average trading volume of 1,500,000 shares, the days-to-cover ratio is currently 2.6 days. Approximately 0.2% of the shares of the company are short sold.
View Novartis' Short Interest
.

When is Novartis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 16th 2024.
View our NVS earnings forecast
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings data on Tuesday, April, 23rd. The company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.07. The business had revenue of $11.83 billion for the quarter, compared to the consensus estimate of $11.50 billion. Novartis had a net margin of 31.33% and a trailing twelve-month return on equity of 32.15%.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Friday, March 1st. Investors of record on Friday, March 8th will be paid a dividend of $3.7772 per share on Thursday, March 7th. This represents a yield of 3.1%. The ex-dividend date of this dividend is Thursday, March 7th. This is an increase from the stock's previous annual dividend of $3.47.
Read our dividend analysis for NVS
.

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.43 per share and currently has a dividend yield of 2.30%. The dividend payout ratio is 32.79%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 29.71% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What ETFs hold Novartis' stock?

ETFs with the largest weight of Novartis (NYSE:NVS) stock in their portfolio include American Century Focused Large Cap Value ETF (FLV).Avantis International Equity ETF (AVDE).

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

Who are Novartis' major shareholders?

Novartis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (0.13%), Principal Financial Group Inc. (0.12%), Mondrian Investment Partners LTD (0.10%), Magnetar Financial LLC (0.09%), Scharf Investments LLC (0.06%) and Capital Research Global Investors (0.04%).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Novartis have any subsidiaries?
The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
This page (NYSE:NVS) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners